{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:19Z","timestamp":1791588919529,"version":"4.3.4"},"reference-count":160,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pruritus is defined as an unpleasant sensation that elicits a desire to scratch. Nearly a third of the world\u2019s population may suffer from pruritus during their lifetime. This symptom is widely observed in numerous inflammatory skin diseases\u2014e.g., approximately 70\u201390% of patients with psoriasis and almost every patient with atopic dermatitis suffer from pruritus. Although the pathogenesis of atopic dermatitis and psoriasis is different, the complex intricacies between several biochemical mediators, enzymes, and pathways seem to play a crucial role in both conditions. Despite the high prevalence of pruritus in the general population, the pathogenesis of this symptom in various conditions remains elusive. This review aims to summarize current knowledge about the pathogenesis of pruritus in psoriasis and atopic dermatitis. Each molecule involved in the pruritic pathway would merit a separate chapter or even an entire book, however, in the current review we have concentrated on some reports which we found crucial in the understanding of pruritus. However, the pathomechanism of pruritus is an extremely complex and intricate process. Moreover, many of these signaling pathways are currently undergoing detailed analysis or are still unexplained. As a result, it is currently difficult to take an objective view of how far we have come in elucidating the pathogenesis of pruritus in the described diseases. Nevertheless, considerable progress has been made in recent years.<\/jats:p>","DOI":"10.3390\/ijms241914734","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:42:08Z","timestamp":1695973328000},"page":"14734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-0441","authenticated-orcid":false,"given":"Agnieszka","family":"Kaczmarska","sequence":"first","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3268-012X","authenticated-orcid":false,"given":"Dominika","family":"Kwiatkowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna Konstancja","family":"Skrzypek","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Wroclaw Medical University, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew Tadeusz","family":"Kowalewski","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Wroclaw Medical University, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Jaworecka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzesz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in Adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: A population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_5","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.08.026","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy","volume":"62","author":"Menter","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1067\/mjd.2001.116347","article-title":"Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in japanese patients with moder-ate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"New Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","article-title":"Greater Cumulative Benefits from Ixekizumab versus Ustekinumab Treatment over 52 Weeks for Patients with Moder-ate-to-Severe Psoriasis in a Randomized, Double-Blinded Phase 3b Clinical Trial","volume":"31","author":"Blauvelt","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and Safety of Acitretin in Three Fixed Doses of 25, 35 and 50 mg in Adult Patients with Severe Plaque Type Psoriasis: A Randomized, Double Blind, Parallel Group, Dose Ranging Study","volume":"27","author":"Dogra","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09546634.2018.1535690","article-title":"Safety and Effectiveness of Conventional Systemic Therapy and Biological Drugs in Patients with Moderate to Severe Psoriasis and HIV Infection: A Retrospective Multicenter Study","volume":"30","author":"Aparicio","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): A 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2018.03.040","article-title":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials","volume":"79","author":"Gold","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2000.107940","article-title":"Tazarotene plus UVB phototherapy in the treatment of psoriasis","volume":"43","author":"Koo","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1590\/abd1806-4841.20186723","article-title":"Tazarotene gel with narrow-band UVB phototherapy: A synergistic combination in psoriasis","volume":"93","author":"Dayal","year":"2018","journal-title":"An. Bras. De. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Deckers, I.A.G., McLean, S., Linssen, S., Mommers, M., van Schayck, C.P., and Sheikh, A. (2012). Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiological studies. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039803"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaci.2007.11.004","article-title":"Is eczema really on the increase worldwide?","volume":"121","author":"Williams","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/all.12112","article-title":"Characterization of different courses of atopic dermatitis in adolescent and adult patients","volume":"68","author":"Garmhausen","year":"2013","journal-title":"Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e190025","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of Atopic Dermatitis with Sleep Quality in Children","volume":"173","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2500\/aap.2017.38.4005","article-title":"Atopic dermatitis: Burden of illness, quality of life, and associated complications","volume":"38","author":"Drucker","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: Part I\u2014Systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic Treatment of Adult Atopic Dermatitis: A Review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase iii trials (ecztra 1 and ecztra 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1468-3083.2007.02234.x","article-title":"Itch in the community: Associations with psychosocial factors among adults","volume":"21","author":"Dalgard","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CCID.S4465","article-title":"Itch in psoriasis: Epidemiology, clinical aspects and treatment options","volume":"2","author":"Prignano","year":"2009","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejp.768","article-title":"Pruritus in psoriasis: An update","volume":"20","author":"Szepietowski","year":"2016","journal-title":"Eur. J. Pain."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.sder.2011.05.002","article-title":"Management of Itch in Atopic Dermatitis","volume":"30","author":"Hong","year":"2011","journal-title":"Semin. Cutan. Med. Surgery. Semin. Cutan. Med. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Jaworecka, K., Rzepko, M., Marek-J\u00f3zefowicz, L., Tamer, F., Stefaniak, A.A., Szczegielniak, M., Chojnacka-Purpurowicz, J., Gulekon, A., Szepietowski, J.C., and Narbutt, J. (2022). The Impact of Pruritus on the Quality of Life and Sleep Disturbances in Pa-tients Suffering from Different Clinical Variants of Psoriasis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195553"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2340\/00015555-3065","article-title":"Influence of Itch and Pain on Sleep Quality in Atopic Dermatitis and Psoriasis","volume":"99","author":"Kaaz","year":"2019","journal-title":"Acta Derm.-Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kahremany, S., Hofmann, L., Gruzman, A., and Cohen, G. (2020). Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144883"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000518220","article-title":"Pruritus, Pain, and Depression Associated with the Most Common Skin Diseases: Data from the French Study \u201cObjectifs Peau\u201d","volume":"238","author":"Huet","year":"2022","journal-title":"Dermatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaci.2023.04.006","article-title":"Neuropathic pruritus","volume":"152","author":"Kwatra","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1000110","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 Cytokines and Atopic Dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J. Clin. Cell. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms regulating skin immunity and inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1083\/jcb.201603042","article-title":"The cell biology of acute itch","volume":"213","author":"Green","year":"2016","journal-title":"J. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/exd.14014","article-title":"Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus","volume":"28","author":"Nakashima","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuron.2018.03.023","article-title":"Peripheral and Central Mechanisms of Itch","volume":"98","author":"Dong","year":"2018","journal-title":"Neuron"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., and Offidani, A. (2021). Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111511"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jdv.15450","article-title":"Itch: An under-recognized problem in psoriasis","volume":"33","author":"Elewski","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5021\/ad.2020.32.1.1","article-title":"Characteristics of Pruritus according to Morphological Phenotype of Psoriasis and Association with Neuropeptides and Interleukin-31","volume":"32","author":"Park","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jdv.15539","article-title":"Pruritus characteristics in a large Italian cohort of psoriatic patients","volume":"33","author":"Damiani","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-019-01998-7","article-title":"Pruritus and sleep disturbances in patients with psoriasis","volume":"312","author":"Hawro","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_62","unstructured":"Sanchez, D.P., and Sonthalia, S. (2020). StatPearls, StatPearls Publishing LLC."},{"key":"ref_63","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semcancer.2022.03.002","article-title":"Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers","volume":"86","author":"Arora","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdermsci.2011.11.007","article-title":"Chemokine receptors in the pathogenesis and therapy of psoriasis","volume":"65","author":"Mabuchi","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Purzycka-Bohdan, D., Nedoszytko, B., Zab\u0142otna, M., Gle\u0144, J., Szczerkowska-Dobosz, A., and Nowicki, R.J. (2022). Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113330"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2340\/00015555-1709","article-title":"Variations in serum TARC and I-TAC levels reflect minor changes in disease activity and pruritus in atopic dermatitis","volume":"94","author":"Kimura","year":"2014","journal-title":"Acta Derm. -Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/1346-8138.15511","article-title":"Thymus and activation-regulated chemokine (TARC) in patients with psoriasis: Increased serum TARC levels in patients with generalized pustular psoriasis","volume":"47","author":"Kawasaki","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a Clinical Target for Pruritus Treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2133.2011.10347.x","article-title":"Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch","volume":"165","author":"Taneda","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jdermsci.2017.07.019","article-title":"Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE","volume":"87","author":"Salz","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2340\/00015555-1345","article-title":"Serum IL-31 Levels are Increased in Patients with Cutaneous T-Cell Lymphoma","volume":"92","author":"Ohmatsu","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/aap.2017.38.4080","article-title":"Interleukin 31 and skin diseases: A sys-tematic review","volume":"38","author":"Gangemi","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The Pruritus- and TH2-associated Cytokine IL-31 Promotes Growth of Sensory Nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5114\/ada.2021.108926","article-title":"Significance of interleukin-31 (IL-31) gene polymorphisms and IL-31 serum level in psoriasis in correlation with pruritus","volume":"38","author":"Nedoszytko","year":"2021","journal-title":"Postepy Dermatol. Allergol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Singh, B., Jegga, A.G., Shanmukhappa, K.S., Edukulla, R., Khurana Hershey, G.H., Medvedovic, M., Dillon, S.R., and Madala, S.K. (2016). IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier func-tion. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161877"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/exd.12222","article-title":"A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice","volume":"22","author":"Arai","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_81","first-page":"426","article-title":"Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations","volume":"32","author":"Adamski","year":"2015","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41551-018-0328-5","article-title":"Interleukin-31-mediated photoablation of pruritogenic epidermal neurons reduces itch-associated behaviours in mice","volume":"3","author":"Nocchi","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-012-1293-6","article-title":"Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients","volume":"305","author":"Narbutt","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/CCID.S257647","article-title":"IL-33\/13 axis and IL-4\/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis","volume":"13","author":"Bodoor","year":"2020","journal-title":"Clin. Cosm. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.2007.48","article-title":"Psoriasis is associated with increased beta-defensin genomic copy number","volume":"40","author":"Hollox","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2340\/00015555-2801","article-title":"Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm. -Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bbadis.2014.02.007","article-title":"Receptors, cells and circuits involved in pruritus of systemic disorders","volume":"1842","author":"Kremer","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/32904","article-title":"Altered nociception, analgesia and aggression in mice lacking the receptor for substance P","volume":"392","author":"Herrero","year":"1998","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13555-019-0305-2","article-title":"NK-1 Receptor Antagonists and Pruritus: Review of Current Literature","volume":"9","author":"Jaworecka","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.npep.2005.03.004","article-title":"The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines","volume":"39","author":"Rosso","year":"2005","journal-title":"Neuropeptides"},{"key":"ref_93","first-page":"383","article-title":"Effect of cetirizine hydrochloride on the expression of substance P receptor and cytokines production in human epidermal keratinocytes and dermal fibroblasts","volume":"43","author":"Liu","year":"2008","journal-title":"Yao Xue Xue Bao = Acta Pharm. Sin."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"064727","DOI":"10.1155\/2007\/64727","article-title":"Mediators of pruritus in psoriasis","volume":"2007","author":"Reich","year":"2007","journal-title":"Mediat. Inflamm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2133.2003.05586.x","article-title":"Pruritogenic mediators in psoriasis vulgaris: Comparative evaluation of itch-associated cutaneous factors","volume":"149","author":"Nakamura","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2340\/00015555-0265","article-title":"Plasma neuropeptides and perception of pruritus in psoriasis","volume":"87","author":"Reich","year":"2007","journal-title":"Acta Derm. -Venereol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/CCID.S216422","article-title":"Effect of narrowband ultraviolet B therapy on serum levels of CD26\/dipeptidyl-peptidase IV and truncated forms of substance P in psoriasis patients with pruritus","volume":"12","author":"Kongthong","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000270385","article-title":"Responses to Intradermal Injections of Substance P in Psoriasis Patients with Pruritus","volume":"23","author":"Amatya","year":"2010","journal-title":"Ski. Pharmacol. Physiol."},{"key":"ref_99","first-page":"1858","article-title":"Reduction of serum soluble CD26\/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus","volume":"29","author":"Kobayashi","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0168-8278(97)80180-8","article-title":"Aberrant dipeptidyl peptidase IV (DPP IV\/CD26) expression in human hepatocellular carcinoma","volume":"27","author":"Stecca","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.stem.2010.04.001","article-title":"A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer","volume":"6","author":"Pang","year":"2010","journal-title":"Cell Stem Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-06-0361","article-title":"Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with reti-noblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix","volume":"12","author":"Inamoto","year":"2006","journal-title":"Clin. Cancer. Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Komiya, E., Tominaga, M., Kamata, Y., Suga, Y., and Takamori, K. (2020). Molecular and cellular mechanisms of itch in psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218406"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jdermsci.2017.03.005","article-title":"A possible role for CD26\/DPPIV enzyme activity in the regulation of psoriatic pruritus","volume":"86","author":"Komiya","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Perro","year":"2014","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1096\/fj.13-229948","article-title":"TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis","volume":"27","author":"Liu","year":"2013","journal-title":"FASEB J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/jid.2011.60","article-title":"Cutaneous denervation of psoriasiform mouse skin im-proves acanthosis and inflammation in a sensory neuropeptide-dependent manner","volume":"131","author":"Ostrowski","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1096\/fj.201800395RR","article-title":"Sensory nerves mediate spontaneous behaviors in addition to inflammation in a murine model of psoriasis","volume":"33","author":"Kodji","year":"2019","journal-title":"FASEB J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/0960327121991911","article-title":"Gene expression profiles of transient receptor potential (TRP) channels in the peripheral blood mononuclear cells of psoriasis patients","volume":"40","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/wrr.12469","article-title":"Increased activity of TRPV3 in keratinocytes in hypertrophic burn scars with postburn pruritus","volume":"24","author":"Kim","year":"2016","journal-title":"Wound Repair. Regen."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jid.2020.02.028","article-title":"Enhanced Thermal Sensitivity of TRPV3 in Keratinocytes Underlies Heat-Induced Pruritogen Release and Pruritus in Atopic Dermatitis","volume":"140","author":"Seo","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"790435","DOI":"10.3389\/fnmol.2021.790435","article-title":"Abnormal Somatosensory Behaviors Associated With a Gain-of-Function Mutation in TRPV3 Channels","volume":"14","author":"Fatima","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Um, J.Y., Kim, H.B., Kim, J.C., Park, J.S., Lee, S.Y., Chung, B.Y., Park, C.W., and Kim, H.O. (2022). TRPV3 and Itch: The Role of TRPV3 in Chronic Pruritus according to Clinical and Experimental Evidence. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314962"},{"key":"ref_114","first-page":"723","article-title":"Inhibition of temperature-sensitive TRPV3 channel by two natural iso-chlorogenic acid isomers for alleviation of dermatitis and chronic pruritus. Acta Pharm","volume":"12","author":"Qi","year":"2022","journal-title":"Sin. B"},{"key":"ref_115","first-page":"8312946","article-title":"Effects of the Fruit Extract of Tribulus terrestris on Skin Inflammation in Mice with Oxazolone-Induced Atopic Dermatitis through Regu-lation of Calcium Channels, Orai-1 and TRPV3, and Mast Cell Activation. Evidence-based Complement","volume":"2017","author":"Kang","year":"2017","journal-title":"Altern. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1080\/13880209.2017.1300819","article-title":"Spirodela polyrhiza extract modulates the activation of atopic dermatitis-related ion channels, Orai1 and TRPV3, and inhibits mast cell degranulation","volume":"55","author":"Nam","year":"2017","journal-title":"Pharm. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.118.254045","article-title":"Pharmacological Inhibition of the Temperature-Sensitive and Ca2+-Permeable Transient Receptor Potential Vanilloid TRPV3 Channel by Natural Forsythoside B Attenuates Pruritus and Cytotoxicity of Keratinocytes","volume":"368","author":"Zhang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2020.01.004","article-title":"Anti-pruritic and anti-inflammatory effects of natural verbascoside through selective inhibition of temperature-sensitive Ca2+-permeable TRPV3 channel","volume":"97","author":"Sun","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1111\/bph.15913","article-title":"Scutellarein attenuates atopic dermatitis by selectively inhibiting transient receptor potential vanilloid 3 channels","volume":"179","author":"Wang","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1476-5381.2011.01568.x","article-title":"17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception","volume":"165","author":"Bang","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/bph.15390","article-title":"A plant-derived TRPV3 inhibitor suppresses pain and itch","volume":"178","author":"Han","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve Growth Factor: Early Studies and Recent Clinical Trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_123","first-page":"769","article-title":"Pruritus and nerve growth factor in psoriasis","volume":"43","author":"Choi","year":"2005","journal-title":"Korean J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"110063","DOI":"10.1016\/j.intimp.2023.110063","article-title":"Nerve growth factor mediates activation of transient receptor potential vanilloid 1 in neurogenic pruritus of psoriasis","volume":"118","author":"Shang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jdermsci.2008.08.011","article-title":"Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis","volume":"53","author":"Yamaguchi","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid receptors","volume":"67","author":"Stein","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-0625.2009.00844.x","article-title":"Opioids and the skin\u2013where do we stand?","volume":"18","author":"Bigliardi","year":"2009","journal-title":"Exp. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2340\/00015555-2595","article-title":"Opioid Receptors in Psoriatic Skin: Relationship with Itch","volume":"97","author":"Kupczyk","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of Pruritus with Topically Applied Opiate Receptor Anatagonist","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000079211","article-title":"Histamine, Substance P and Calcitonin Gene-Related Peptide Plasma Concentration and Pruritus in Patients Suffering from Psoriasis","volume":"5","author":"Szepietowski","year":"2004","journal-title":"Dermatol. Psychosom."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/000155598441503","article-title":"Studies on mast cells and histamine release in psoriasis: The effect of ranitidine","volume":"78","author":"Petersen","year":"1998","journal-title":"Acta Derm. Venereol."},{"key":"ref_132","first-page":"457","article-title":"Antihistamines in the treatment of pruritus in psoriasis","volume":"34","author":"Szepietowski","year":"2017","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajpath.2011.09.028","article-title":"Human Memory Th17 Cells Express a Functional His-tamine H4 Receptor","volume":"180","author":"Mommert","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"adv00342","DOI":"10.2340\/00015555-3674","article-title":"Histamine 2 receptor agonism and his-tamine 4 receptor antagonism ameliorate inflammation in a model of psoriasis","volume":"100","author":"Rossbach","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic Dermatitis: Pathophysiology","volume":"1027","author":"Boothe","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s004840000077","article-title":"Influence of weather and climate on subjective symptom intensity in atopic eczema","volume":"45","author":"Vocks","year":"2001","journal-title":"Int. J. Biometeorol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/exd.13981","article-title":"Why does sweat lead to the development of itch in atopic dermatitis?","volume":"12","author":"Murota","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","article-title":"Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications","volume":"2","author":"Czarnowicki","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.4049\/jimmunol.1300300","article-title":"TRPA1-Dependent Pruritus in IL-13\u2013Induced Chronic Atopic Dermatitis","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"key":"ref_141","first-page":"8","article-title":"TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery","volume":"62","author":"Yun","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2014.01.178","article-title":"Differential processing of mammalian l-histidine decarboxylase enzymes","volume":"445","author":"Fennell","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ajpath.2015.07.015","article-title":"Histamine released from epidermal keratinocytes plays a role in \u03b1-melanocyte\u2013stimulating hormone-induced itching in mice","volume":"185","author":"Shimizu","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2340\/00015555-2559","article-title":"Expression of histidine decarboxylase in the epidermis of primates with chronic itch","volume":"97","author":"Inami","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjd.13199","article-title":"The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin","volume":"171","author":"Greenwald","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s40257-020-00538-8","article-title":"The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic Itch","volume":"21","author":"Li","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/ijd.IJD_136_19","article-title":"Is Itch Intensity in Atopic Dermatitis Associated with Skin Colonization by Staphylococcus aureus?","volume":"65","author":"Blicharz","year":"2020","journal-title":"Indian J. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaci.2009.09.052","article-title":"Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid","volume":"125","author":"Travers","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: Signaling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaci.2012.05.027","article-title":"Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis","volume":"130","author":"Murota","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.M011615200","article-title":"The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCs): Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2","volume":"276","author":"Michelsen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbrc.2014.12.115","article-title":"AP-57\/C10orf99 is a new type of multifunctional antimicrobial peptide","volume":"457","author":"Yang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuron.2019.01.012","article-title":"A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain","volume":"101","author":"Green","year":"2019","journal-title":"Neuron"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygeno.2013.11.001","article-title":"Gene expression profile based classification models of psoriasis","volume":"103","author":"Guo","year":"2014","journal-title":"Genomics"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"eabm7342","DOI":"10.1126\/sciadv.abm7342","article-title":"GPR15L is an epithelial inflammation-derived pruritogen","volume":"8","author":"Tseng","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.13679","article-title":"TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis","volume":"30","author":"Nygaard","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Teixeira","year":"2021","journal-title":"Lancet"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/jdv.18137","article-title":"Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: A real-life experience","volume":"36","author":"Napolitano","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbi.2021.08.211","article-title":"Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis","volume":"98","author":"Xiao","year":"2021","journal-title":"Brain Behav. Immun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:02:00Z","timestamp":1760130120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":160,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ijms241914734"],"URL":"https:\/\/doi.org\/10.3390\/ijms241914734","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}